Abstract 988P
Background
Liver cancer is a leading cause of cancer-related mortality worldwide. There is a literature gap regarding its burden in the Middle East and North Africa (MENA) region. Therefore, we aimed to investigate the epidemiological trends of primary liver cancer in the MENA region from 1990 to 2019.
Methods
The Global Burden of Disease database was used to extract the age-standardized rates per 100,000 population for prevalence (ASRP), incidence (ASRI), and years lived with disability (YLDs) of primary liver cancer in the MENA region between 1990 and 2019. Data were analyzed to identify regional distribution patterns across different countries and demographic groups using Wilcoxon signed-rank test.
Results
ASRP for liver cancer in the MENA region was significantly higher in 2019 compared to 1990 (median of 4.34 and 5.38 in 1990 and 2019, respectively; P= 0.002). The major causes of primary liver cancer were hepatitis C virus, followed by hepatitis B virus, nonalcoholic steatohepatitis, and alcohol use. In 2019, the highest ASRP was observed in Qatar (24.894; 95% confidence interval (CI): 18.34-33.24) and Egypt (22.575; 95% CI: 16.20-30.90), while Morocco had the lowest one (2.21; 95% CI: 1.68-2.70). On the other hand, no significant increase was observed from 1990 to 2019 for the ASRI (median of 4.26 and 4.49 in 1990 and 2019, respectively, P = 0.498) and YLDs (median of 0.96 and 1.04 in 1990 and 2019, respectively, P = 0.079).
Conclusions
The prevalence of liver cancer shows a rising trend in the MENA region from 1990 to 2019. Adopting regional programs to address the major risk factors should be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18